PAYER POLICY CHANGES

Q0221 Insurance Policy Changes

HCPCS Q0221 is officially defined as "Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 600 mg." HCPCS Q0221 is referenced in 1 tracked payer policy change from Colorado Medicaid. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS Q0221 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Watch Q0221

Get one email when a payer policy names Q0221, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

See every payer rule for Q0221

Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for Q0221 in one place.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.